Low Blood Glucose Index and Hypoglycaemia Risk: Insulin Glargine 300 U/mL Versus Insulin Glargine 100 U/mL in Type 2 Diabetes

被引：0
|
作者：
Boris Kovatchev
Zhaoling Meng
Anna M. G. Cali
Riccardo Perfetti
Marc D. Breton
机构：
[1] University of Virginia,Center for Diabetes Technology
[2] Sanofi,undefined
[3] Sanofi,undefined
来源：
Diabetes Therapy | 2020年 / 11卷
关键词：
Basal insulin; Glycaemic variability; Hypoglycaemia; Insulin glargine; Type 2 diabetes;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1293 / 1302
页数：9
相关论文
共 50 条
  • [41] Efficacy and Safety of Insulin Glargine 300U/mL versus 100U/mL in Diabetes Mellitus: A Comprehensive Review of the Literature
    Vargas-Uricoechea, Hernando
    JOURNAL OF DIABETES RESEARCH, 2018, 2018
  • [42] Insulin Glargine 300 U/mL Therapy in Children and Adolescents with Type 1 Diabetes
    Claudio Maffeis
    Ivana Rabbone
    Pediatric Drugs, 2022, 24 : 499 - 512
  • [43] New insulin glargine 300 U/ml compared with glargine 100 U/ml in insulin-naive people with type 2 diabetes on oral glucose-lowering drugs: a randomized controlled trial (EDITION 3)
    Bolli, G. B.
    Riddle, M. C.
    Bergenstal, R. M.
    Ziemen, M.
    Sestakauskas, K.
    Goyeau, H.
    Home, P. D.
    DIABETES OBESITY & METABOLISM, 2015, 17 (04): : 386 - 394
  • [44] Improved real-world outcomes for type 2 diabetes patients on basal-bolus insulin therapy switching to insulin glargine 300 U/ml vs. insulin glargine 100 U/ml and insulin Detemir
    Wu, Jasmanda
    Bailey, Timothy S.
    Bosnyak, Zsolt
    Westerbacka, Jukka
    Gupta, Rishab A.
    Menon, Arjun A.
    Nicholls, Charlie
    Blonde, Lawrence
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2019, 28 : 416 - 417
  • [45] Efficacy and Safety of Switching from Insulin Glargine 100 U/mL to the Same Dose of Glargine 300 U/mL in Japanese Type 1 and 2 Diabetes Patients: A Retrospective Analysis
    Nakanishi, Shuhei
    Iwamoto, Masahiro
    Kamei, Shinji
    Hirukawa, Hidenori
    Shimoda, Masashi
    Tatsumi, Fuminori
    Kohara, Kenji
    Obata, Atsushi
    Kimura, Tomohiko
    Kinoshita, Tomoe
    Irie, Shintaro
    Sanada, Junpei
    Fushimi, Yoshiro
    Nishioka, Momoyo
    Mizoguchi, Akiko
    Kameyama, Miyuki
    Mune, Tomoatsu
    Kaku, Kohei
    Kaneto, Hideaki
    INTERNAL MEDICINE, 2018, 57 (10) : 1381 - 1389
  • [46] New Insulin Glargine 300 U/mL for the Treatment of Type 1 and Type 2 Diabetes Mellitus
    Goldman, Jennifer
    White, John R., Jr.
    ANNALS OF PHARMACOTHERAPY, 2015, 49 (10) : 1153 - 1161
  • [47] New insulin glargine 300U/ml in Type 2 diabetes using basal plus meal-time insulin: sustained glycaemic control and less hypoglycaemia compared with glargine 100U/ml (EDITION 1)
    Home, P. D.
    Yki-Jarvinen, H.
    Bolli, G. B.
    Cissokho, S.
    Riddle, M. C.
    DIABETIC MEDICINE, 2015, 32 : 78 - 78
  • [48] Glycaemic control and hypoglycaemia in people with type 2 diabetes switching from twice-daily basal insulin to once-daily insulin glargine 300 U/mL or insulin glargine 100 U/mL (EDITION 1 and EDITION 2 subgroup analysis)
    Roussel, Ronan
    d'Emden, Michael C.
    Fisher, Miles
    Javier Ampudia-Blasco, F.
    Stella, Peter
    Bizet, Florence
    Cali, Anna M. G.
    Wysham, Carol H.
    DIABETES OBESITY & METABOLISM, 2018, 20 (02): : 448 - 452
  • [49] Clinical Pharmacokinetics and Pharmacodynamics of Insulin Glargine 300 U/mL
    Jennifer N. Clements
    Tiffaney Threatt
    Eileen Ward
    Kayce M. Shealy
    Clinical Pharmacokinetics, 2017, 56 : 449 - 458
  • [50] Clinical Pharmacokinetics and Pharmacodynamics of Insulin Glargine 300 U/mL
    Clements, Jennifer N.
    Threatt, Tiffaney
    Ward, Eileen
    Shealy, Kayce M.
    CLINICAL PHARMACOKINETICS, 2017, 56 (05) : 449 - 458
12345